(Q43992052)

28 November 2017

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives (English)

1 reference

polycystic ovary syndrome

28 November 2017

1 reference

1 reference

1 reference

George Mastorakos

1

1 reference

28 November 2017

Carolina Koliopoulos

series ordinal

2

1 reference

28 November 2017

George Creatsas

series ordinal

3

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

28 November 2017

Fertility and Sterility

1 reference

28 November 2017

77

1 reference

28 November 2017

5

1 reference

28 November 2017

919-927

1 reference

Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Polycystic ovary syndrome. Phenotype to genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Relevance of the determination of ovarian volume in adolescent girls with menstrual disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH analog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Metabolic approaches to the subclassification of polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Obesity, lipids, cardiovascular risk, and androgen excess

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Clinical assessment of body hair growth in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Changes in androgens during treatment with four low-dose contraceptives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Treatment of hirsutism and acne with cyproterone acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Effects of combined desogestrel-ethinylestradiol treatment on lipid profiles in women with polycystic ovarian disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Metabolic aspects of polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Coronary Heart Disease Risk Factors in Women With Polycystic Ovary Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Sex hormone-binding globulin levels in middle-aged premenopausal women. Associations with visceral obesity and metabolic profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

Detection of Functional Ovarian Hyperandrogenism in Women with Androgen Excess

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

The molecular basis of premature adrenarche: an hypothesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2902993-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0015-0282(02)02993-X

1 reference

28 November 2017

1 reference